XNASGUTS
Market cap88mUSD
Jan 15, Last price
1.83USD
1D
2.23%
1Q
-26.51%
IPO
-83.51%
Name
Fractyl Health Inc
Chart & Performance
P/E
—
P/S
733.51
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
120k
Net income
-77m
L+65.95%
CFO
-43m
L-7.40%
Profile
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is based in Lexington, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 120 | ||||
Cost of revenue | 38,115 | 49,385 | |||
Unusual Expense (Income) | |||||
NOPBT | (37,995) | (49,385) | |||
NOPBT Margin | |||||
Operating Taxes | |||||
Tax Rate | |||||
NOPAT | (37,995) | (49,385) | |||
Net income | (77,091) 65.95% | (46,453) 19.93% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | (511) | 321 | |||
BB yield | |||||
| Debt | |||||
Debt current | 2,731 | 1,250 | |||
Long-term debt | 114,899 | 305,555 | |||
Deferred revenue | |||||
Other long-term liabilities | 306,426 | 874 | |||
Net debt | 80,166 | 253,281 | |||
| Cash flow | |||||
Cash from operating activities | (42,823) | (46,243) | |||
CAPEX | (359) | (56) | |||
Cash from investing activities | (359) | (56) | |||
Cash from financing activities | 27,437 | 4,350 | |||
FCF | (67,120) | (49,687) | |||
| Balance | |||||
Cash | 33,209 | 49,269 | |||
Long term investments | 4,255 | 4,255 | |||
Excess cash | 37,458 | 53,524 | |||
Stockholders' equity | (346,616) | 17,805 | |||
Invested Capital | 414,371 | 37,090 | |||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 47,607 | 47,607 | |||
Price | |||||
Market cap | |||||
EV | |||||
EBITDA | (37,709) | (48,933) | |||
EV/EBITDA | |||||
Interest | |||||
Interest/NOPBT | |||||